Low-Dose Naltrexone for Chronic Fatigue Syndrome
This trial will study whether low-dose naltrexone can help with symptoms of Post-COVID-19 Fatigue Syndrome. LDN is a medication that is given in doses of 1-4.5 mg and is safe and well-tolerated. It may help to reduce pain and inflammation and improve well-being and immune function.
- Chronic Fatigue Syndrome (CFS)
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2020 Phase 2 trial • 43 Patients • NCT04409041
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Does this clinical experiment accept participants under the age of 30?
"As specified in the trial's eligibility guidelines, 19 is the lowest age of admission while 69 marks the upper limit."
Are there any existing opportunities to become involved in this research endeavor?
"Clinicaltrials.gov reports that this research is not presently enrolling patients; the trial was first posted on March 1st 2023 and last updated December 6th 2022. Nevertheless, 1617 other clinical trials are actively seeking participants as of now."
Can I be included in this exploration?
"This medical trial requires 160 participants, aged between 19 and 69 years old who have the specified syndrome. For eligibility in this study, individuals must accept contraception for its duration if female, maintain regular medications dose unless essential changes are prescribed by a doctor, verify SARS-CoV-2 case status within 3 to 6 months of recruitment through testing or clinical confirmation from a physician, and meet all relevant diagnostic criteria as authenticated by PCRC."
Is Low-Dose Naltrexone sanctioned by the FDA?
"Despite the lack of efficacy data, Low-Dose Naltrexone is thought to be relatively safe and thus was assigned a rating of 2."